According to RAPS.org, the Trans-Pacific Partnership (TPP) recently came to a compromise that would “provide eight years of exclusivity to biologic drugs, or provide five years of exclusivity, plus up to three more years under a regulatory framework for the 12 countries in the trade bloc, which includes the US, Australia, New Zealand, Canada, Japan and Malaysia.”
Industry organizations have expressed disapproval in the compromise, specifically the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Biotechnology Industry Organization (BIO), because they believe it will halt innovation and development within the industry.
On the opposite side of the spectrum, organizations like Doctors without Borders (MSF) have expressed distaste due to the timespan being longer than expected. The compromise sets the exclusivity to eight years, whereas such organizations preferred a shorter amount of time. They believe the new agreement would negatively affect developing countries and people’s access to affordable medicine.
For the next three months, each side will argue their case before Congress. So far, Republicans are leaning toward the industry’s opinion, while Democrats are favoring the other side.
For more information, visit Zachary Brennan’s article on RAPS.org.
To read more about the topic, click here.